Opendata, web and dolomites

NovAnI SIGNED

Indentification and optimisation of novel anti-infective agents using multiple hit-identification strategies

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 NovAnI project word cloud

Explore the words cloud of the NovAnI project. It provides you a very rough idea of what is the project "NovAnI" about.

strategies    hit    provides    million    synthetic    infective    explored    tuberculosis    sliding    biochemists    antibacterial    flexibility    clamp    dnan    interdisciplinary    der    staphylococcus    pathogens    position    coupling    return    rapid    infections    infectives    difficult    anti    negative    expertise    vitamin    inhibitors    edge    synergistic    antimalarial    crossing    potentially    methicillin    emergence    medicinal    protein    action    identification    repair    fact    context    biochemical    serious    first    resistance    diseases    mode    bacteria    crystallographers    causative    excellent    drug    thereby    importers    mycobacterium    gram    cell    absent    dxs    me    combination    resistant    exhaustion    collaborations    deaths    pharmacologists    humans    employing    investment    give    mrsa    biosynthetic    chemistry    organic    scaffolds    un    molecule    dna    transporters    energy    circumventing    wall    health    builds    aureus    unconventional    small    given    agent    erc    cutting    incidence    positive    polymerase    agents    peculiar    few    drugs    platform    threat    selectivity    antituberculotic    place    urgently    goals   

Project "NovAnI" data sheet

The following table provides information about the project.

Coordinator
HELMHOLTZ-ZENTRUM FUR INFEKTIONSFORSCHUNG GMBH 

Organization address
address: INHOFFENSTRASSE 7
city: BRAUNSCHWEIG
postcode: 38124
website: www.helmholtz-hzi.de

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Germany [DE]
 Total cost 1˙499˙367 €
 EC max contribution 1˙499˙367 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2017-STG
 Funding Scheme ERC-STG
 Starting year 2018
 Duration (year-month-day) from 2018-02-01   to  2023-01-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    HELMHOLTZ-ZENTRUM FUR INFEKTIONSFORSCHUNG GMBH DE (BRAUNSCHWEIG) coordinator 1˙499˙367.00

Map

 Project objective

Given the rapid emergence of anti-infective resistance, drugs with a novel mode of action are urgently needed. Because of an exhaustion of existing strategies, a low return on investment and the fact that anti-infectives are difficult to develop (e.g., crossing the peculiar cell wall of Mycobacterium tuberculosis), promising un(der)explored targets and unconventional hit-identification strategies are needed.

I have selected three anti-infective targets based on their biochemical context for which few or no small-molecule inhibitors are known:

1) The antimalarial and antituberculotic drug target DXS is part of a unique biosynthetic pathway for pathogens that is absent in humans, thereby circumventing selectivity issues. Both diseases are a serious health threat with around 1.9 million deaths per year. 2) Energy-coupling factor transporters are essential vitamin importers for pathogens such as Staphylococcus aureus, the causative agent of methicillin-resistant Staphylococcus aureus (MRSA) infections. 3) The DNA polymerase sliding clamp DnaN has polymerase and DNA repair activities and is an excellent drug target for the development of antibacterial agents against Gram-negative and –positive bacteria given the low incidence of resistance development.

I will address these targets, employing a unique combination of potentially synergistic hit-identification strategies that take into account protein flexibility, provide access to novel scaffolds and give me a cutting edge for the development of novel anti-infectives.

This ERC proposal builds on my experience with the first two targets and provides an excellent platform for the new target DnaN. My expertise in synthetic organic and medicinal chemistry and established hit-identification strategies together with my collaborations with protein crystallographers, biochemists and pharmacologists place me in an excellent position for not only achieving the goals of this interdisciplinary proposal but also going beyond it.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "NOVANI" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "NOVANI" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

evolSingleCellGRN (2019)

Constraint, Adaptation, and Heterogeneity: Genomic and single-cell approaches to understanding the evolution of developmental gene regulatory networks

Read More  

GelGeneCircuit (2020)

Cancer heterogeneity and therapy profiling using bioresponsive nanohydrogels for the delivery of multicolor logic genetic circuits.

Read More  

MATCH (2020)

Discovering a novel allergen immunotherapy in house dust mite allergy tolerance research

Read More